Primary bone lymphoma (PBL) is a rare primary extranodal lymphoma in the skeletal system that accounts for less than 1% of all lymphomas, about 4--5% of extranodal lymphomas, and about 3% of all malignant bone tumors[@b1][@b2][@b3]. The definition of PBL was controversial in the past, but has been defined in the new version of "WHO pathology and genetics classification of soft tissue and bone tumor"[@b4] in 2013 as: *a kind of malignant tumor composed by malignant lymphocytes, forming single or multiple tumor in the bone, not associated with infringement or violation of other extranodal malignant lymph nodes outside the area.* The disease can occur at any age, with a median age of onset ranging from 40--60 years old, with most of the literature suggesting that the proportion in male patients was slightly higher than in females (1.0--1.8:1), a finding also reported for children[@b5][@b6]. Most PBL cases belong to B cell non-Hodgkin's lymphoma, the most common type being diffuse large B-cell lymphoma (DLBCL)[@b7][@b8][@b9]. Other types include follicular lymphoma, mantle cell lymphoma, B-lymphoblastic lymphoma, small lyphocytic lymphoma and Burkitt lymphoma. PBL's clinical manifestations are not specific but the most common symptoms are pain and mass[@b10][@b11][@b12][@b13]. PBL can occur in various parts of bone tissue, with previous reports showing that the highest incidence were long bones[@b14][@b15][@b16][@b17], but with the change of the PBL definition, multiple sites of bone invasion have also been included in the scope of PBL. After that, there are data suggesting the most common diseased parts were the spine or pelvis[@b7][@b8][@b18]. Current treatments include surgery, radiotherapy and chemotherapy, but there is no standard treatment due to a lack of comparability among the studies, caused by changed PBL definitions.

Since PBL is a rare disease, current studies about PBL are mostly retrospective or case reports and retrospective studies often lasted over more than ten years or even decades[@b13]. In addition, present research results are mostly from the US and Europe, but data from Asia are limited. Here we retrospectively collected and analyzed data from 61 PBL patients admitted to our center from 1997 to 2014, in order to better understand the characteristics, outcome, and prognostic factors of PBL in Chinese population. To the authors' knowledge, this study comprises the largest sample size analyzed in Asia currently.

Patients and Methods
====================

Patients
--------

In this retrospective study, 61 PBL patients from the department of lymphoma of Peking University Cancer Hospital and Institute from January 1997 to January 2014 were included. All patients satisfied the 2013 WHO criteria of PBL[@b4]: lymphoma was restricted to bone and adjacent soft tissue with or without regional lymph node involvement at the time of diagnosis. Patients with lymph node involvement on the other side of the diaphragm, distant bone marrow involvement or any other site of extranodal disease were excluded in this series.

The study was approved by the Ethical committee of Peking University Cancer Hospital and Institute and written informed consent was provided by the patients. All experiments were performed in accordance with relevant guidelines and regulations.

Methods
=======

Information Reviewed
--------------------

The database was established from the medical records including: gender, age, presenting symptoms, involved sites, Eastern Cooperative Oncology Group (ECOG) score[@b19], radiological findings, pathological diagnosis, stage, international prognostic index (IPI)[@b20], treatment modality and treatment response. All patients were followed up by outpatient reviews or by telephone conversations; the last follow-up date was 2015-1-1. Overall survival (OS) was defined as time from pathological diagnosis until death, lost or last follow-up. Progression free survival (PFS) was defined as time from pathological diagnosis until disease progression, lost or last follow-up.

Staging
-------

All patients underwent detailed history and physical examinations, blood tests, imaging (chest X-ray or computer tomography (CT), abdominal B-scan ultrasonography or CT, systemic superficial lymph node B-scan ultrasonography; some patients received a systemic positron emission tomography (PET)/CT examination) as well as bone marrow aspirate and biopsy. Some of the patients received a cerebrospinal fluid examination when the spine was involved. The clinical stage was determined by Ann Arbor staging criteria[@b21]. Stage IE was defined as a solitary bone lesion without lymph node involvement; stage IIE as a solitary bone lesion with regional lymph nodes involvement; and stage IV was the presence of multiple bone lesions with or without regional lymph node involvement.

Response Criteria
-----------------

Response to treatment was assessed by the International Workshop to Standardize Response Criteria in 1999 (IWC), also known as the Cheson criteria[@b22]. The PET/CT review efficiency of some patients was based on the revised edition of malignant lymphoma remission criteria in 2007[@b23].

Statistical methods
-------------------

All data were statistically analyzed by SPSS Statistics for Windows (Version 22.0. Armonk, NY: IBM Corp.). The Kaplan-Meier method was used for survival analysis, and the Log-rank test to analyze the survival rate between the two groups. Variables achieving significant level of P \< 0.05 were entered into the COX proportional hazards regression model to complete multivariable analyses. Independent prognostic factors were determined if they had significant effect in the Cox model (P \< 0.05).

Results
=======

Clinical features
-----------------

The general clinical characteristics of 61 patients are shown in [Table 1](#t1){ref-type="table"}. The proportion of males to females of 61 patients was 1.65:1. The median age was 45 years (range, 13--80 years). The most common initial symptom was local pain, followed by nerve compression and local mass.

The histopathological subtypes of the 61 PBL patients are shown in [Table 2](#t2){ref-type="table"}. DLBCL was the most common histological type, accounting for 55.7% (34 cases), followed by systemic anaplastic large cell lymphoma (ALCL) and B-lymphoblastic lymphoma (B-LBL), 13.1% (8 cases) and 11.5% (7 cases), respectively. Other rare types included: Hodgkin's lymphoma (HL), mantle cell lymphoma (MCL), marginal zone B-cell lymphoma (MZL), T-lymphoblastic lymphoma (T-LBL), as well as two cases of T-cell origin (failed to be classified). T-cell lymphoma accounted for 18.0% of the cases.

The pathogenic sites of the 61 PBL patients are shown in [Table 3](#t3){ref-type="table"}. For single bone invasion, the most common site was pelvic bone (9 cases, 33.3%), followed by the long bone with a total of 8 cases (29.6%). In patients with multiple bone invasions, the most common site was the spine (25 cases, 73.5%), followed by the pelvic bones (17 cases, 50%). In all patients, the incidence of the most common sites were the spine and pelvis bones, followed by the skull, femur and humerus.

Treatments, responses and survival of patients with PBL
-------------------------------------------------------

The treatment modality that 61 PBL patients received are shown in [Table 4](#t4){ref-type="table"}. All patients underwent initial therapy with systemic chemotherapy, of which 37 cases (60.7%) received chemotherapy alone and 24 patients (39.3%) were treated with combined local radiotherapy. 18 patients underwent surgery in which the purpose for 10 patients was to ease spinal cord compression or treat pathological fractures and 8 patients underwent primary lesion resections.

After the initial treatment that all patients completed, 57 patients' clinical data can be evaluated. 32 patients achieved complete remission (CR), 18 patients obtained partial remission (PR) and the overall response rate (ORR) was 87.7% (56.1% CR + 31.6% PR). 3 cases were assessed as stable disease (SD) and 4 cases as progress disease (PD) after initial treatment.

A survival analysis was done for 57 PBL patients with complete follow-up data. The median follow-up was 31 months (range, 3--216 months). By the date of the last follow-up, 35 patients survived (61.4%), 22 deaths occurred (38.6%), of which 20 patients died of tumor progression and 2 died due to the treatment. The 5-year OS was 52.3% with the 5-year PFS being 40.1% ([Fig. 1](#f1){ref-type="fig"}).

Effect of the histopathological subtypes on the prognosis of patients with PBL
------------------------------------------------------------------------------

In this group of patients, in addition to DLBCL, other pathology samples were few and thus the survival among all histopathological subtypes could not be compared. The histopathological subtypes B-cell lymphoma, T-cell lymphoma and Hodgkin's lymphoma showed no significant difference for the survival among this three groups. There was also no significant difference in the survival between patients with DLBCL and non-DLBCL. In addition, no significant difference was found for OS and PFS between ALCL and non-ALCL patients, or between DLBCL patients and ALCL patients ([Table 5](#t5){ref-type="table"}).

Analysis of Survival and prognostic factors in patients with PB-DLBCL
---------------------------------------------------------------------

Given the effects of different histopathological subtypes on survival and the sample size limitation of other pathological types, we only analyzed prognostic factors of 34 DLBCL patients. The median follow-up was 38 months (range, 3--216 months). The 5-year OS was 53.0%, 5-year PFS was 47.0% ([Fig. 2](#f2){ref-type="fig"}).

The Kaplan-Meier method and log-rank test was used to analyze the following factors for univariable analysis: gender, age, pathogenic sites, pathological fractures, B symptoms, ECOG score, LDH levels, soft tissue invasion, lymph node involvement, stage, IPI score, molecular subtypes (germinal center B-cell-like (GCB) vs. non-GCB), treatment modality, response to initial therapy and rituximab use. High ECOG score (≥2), stage IV (stage IV vs. stage I&II), high IPI score (\>2) and unachieved CR in initial therapy were associated with worse OS ([Fig. 3](#f3){ref-type="fig"} and [Table 6](#t6){ref-type="table"}), whereas older age (≥60), B symptoms, high ECOG score (≥2), elevated LDH and unachieved CR in initial therapy were associated with worse PFS ([Figs 3](#f3){ref-type="fig"}, [4](#f4){ref-type="fig"} and [Table 6](#t6){ref-type="table"}).

23 cases out of a total of 34 PB-DLBCL patients were further divided into GCB type (11 cases) and non-GCB type (12 cases), with 5-year OS rates of the 2 groups being 70.1% and 20.0% respectively, but the apparent difference did not reach statistical significance (*P* = 0.193) and also for PFS there was no statistical significance (*P* = 0.299). 20 patients received combined rituximab treatments, but compared with the group without rituximab, OS and PFS were not significantly different (5-year OS 48.4% *vs* 60.6%, *P* = 0.494; 5-year PFS 44.9% *vs* 44.0%, *P* = 0.432). The OS rate of patients with complicated pathologic fractures appeared to be inferior to patients without pathological fractures, but the trend did not reach statistical significance (5-year OS 31.7% *vs* 58.9%, *P* = 0.066) and also PFS rates did not significantly differ between the two groups (*P* = 0.240) ([Table 6](#t6){ref-type="table"}).

Multivariable analysis using a COX proportional hazards regression model showed that the baseline ECOG score and response to initial treatment were independent factors for the OS of PB-DLBCL patients. Response to initial treatment was also an independent risk factor for PFS of the patients ([Table 7](#t7){ref-type="table"}).

Discussion
==========

In previous studies, the definition, clinical characteristics, treatment modalities, and prognosis of PBL remain controversial and most of the present research results are from the US and Europe. In this report, we described a series of Chinese PBL patients using the new 2013 WHO criteria[@b4]. This study comprises the largest sample size analyzed in Asia.

According to previous studies, the majority of PBL belongs to B-cell NHL, the most common type being DLBCL, occurring in about ≥80% of all cases, followed by follicular lymphoma[@b7][@b8][@b9] while T-cell NHL accounts for about 1--5% of all PBL patients in the US and Europe[@b7][@b8][@b14][@b24]. In our study, although DLBCL was the most common histological type (55.7%), the incidence seems to be lower than previous reports in the US and Europe. T-cell lymphoma accounted for 18.0% of all PBL patients in our study. The incidence of T-cell lymphoma was higher than previous reports in the US and Europe but similar to other Asia series[@b18][@b25][@b26]. We believe that this differences are due to regional differences of T-cell lymphoma incidences being higher in Asia than in the US and Europe[@b27].

Most previous studies suggested a predominance of long bone involvement in PBL[@b14][@b15][@b16][@b17]. However, Ramadan *et al.*[@b8] reported that the spine was the most commonly involved site, accounting for one-third of 131 cases. Others studies from China and Japan showed that the pelvis was the most common site of PLB involvement[@b18][@b26][@b28]. In the present study, the most commonly involved sites were the spine and pelvis (both accounting for 42.6%, respectively). The preponderance of pelvis involvement may be a unique characteristic of Asian patients with PBL.

The overall outcome of PBL is controversial. In our study, the overall 5-year OS and PFS of 57 PBL patients was 52.3% and 40.5% and the 5-year OS and PFS of 34 PB-DLBCL patients among them were 54.7% and 49.1%. According to previous reports, 5-year OS of PBL patients were 88%[@b15], 76%[@b7], 57.8%[@b29] and 55%[@b18]. However, although DLBCL accounts for a large proportion (68--83%), these studies did not exclude the effect of histological heterogeneity on survival of PBL; we therefore consider that these data lack comparability. To exclude the effect of different histological type on prognosis, fewer studies have discussed the prognosis of PB-DLBCL alone and suggested that PB-DLBCL has a better prognosis than other types of DLBCL. Wu *et al.*[@b9] reported the 5-year OS of 53 PB-DLBCL cases was 81.1%. Small sample data from India[@b30] showed an 8-year OS and DFS of 21 PB-DLBCL patients of 95.2% and 100%. Heyning *et al.*[@b31] reported that in a group of 36 PB-DLBCL cases from the Netherlands, the 5-year OS was 75%. However, our study did not suggest such a good prognosis of PB-DLBCL, as reported by some other authors. Jawad *et al.*[@b24] reported the 5-year and 10-year OS of 994 PB-DLBCL cases were 61% and 48%, respectively. Ramadan *et al.*[@b8] reported on 131 PBL patients from which the 5-year and 10-year OS of 103 (79%) PB-DLBCL patients were 62% and 41%, respectively. Considering variations in the definition and the treatment of PBL and selection bias in retrospective studies, it is perhaps not surprising that there were quite different outcomes between independent studies.

The prognostic factors of PBL have not been well established. In nodal lymphoma, pathological type is one of the most important prognostic factors. Superior prognosis of PB-DLBCL compared to non-DLBCL patients has been noted by Hsieh *et al.*[@b25] who documented 14 cases of PBL in Taiwan and concluded that the prognosis of B-cell PBL was better than T-cell PBL (P = 0.016). Other studies also reported histological type to be a prognostic factor[@b16][@b32]. However, in our series of PBL patients including B-cell lymphoma, T-cell lymphoma, and Hodgkin's lymphoma, no statistical difference in prognosis was found between the three groups. And neither DLBCL group nor ALCL group showed a superior prognosis when compared to other pathological subtypes. Due to the small sample size, it was not possible to compare further differences in prognosis between the various pathological types. Thus, we believe that the impact of pathological type on prognosis of PBL remains an open question.

To exclude the effect of the pathological type on prognosis, in our study we used univariable and multivariable analyses only on PB-DLBCL patients. The IPI system was developed to assess prognosis in patients with aggressive NHL. High IPI score had been considered as a poor prognostic factor of PBL by Ramadan *et al.*[@b8] , Wu *et al.*[@b9] and Huang *et al.*[@b18], but not by Catlett *et al.*[@b33] and Alencar *et al.*[@b14]. In the present study, IPI and its variants(age, ECOG score, LDH levels, number of extranodal sites and Ann Arbor stage) were analyzed. Univariable analyses showed that IPI score, tumor stage and ECOG score had a significant impact on prognosis, but only the ECOG score was identified to be an independent prognostic factor in multivariable Cox analysis. The prognostic impact of IPI on patients with PLB still requires further discussion. Some studies have suggested that age was an important factor affecting the prognosis of PBL[@b8][@b15][@b16][@b34][@b35]. In our study, although age had an impact on the PFS of PB-DLBCL patients, there was no significant effect of age on OS rates and also multivariable analysis showed no age effect. In addition to ECOG score, whether CR in initial treatment was an independent prognostic factor determining both OS and PFS, which was consistent with some previous reports[@b7][@b36]. A previous study aimed at nodal DLBCL, suggested that the prognosis of the GCB subtype is better than that of the non-GCB subtype in using standard chemotherapy[@b37]. In our study, 23 cases of 34 PB-DLBCL patients could be further divided into GCB type (11 cases) and non-GCB type (12 cases), but the 5-year OS and PFS between the 2 groups did not reach statistical significance, which is in accordance with reports from Bhagavathi *et al.*[@b38] and Heyning *et al.*[@b31], but the sample sizes were small and the influence of molecular subtypes on prognosis remains to be elucidated.

Treatment modalities for PBL include chemotherapy, radiotherapy and surgery which is mainly applied for diagnostic biopsy, to repair pathologic fractures or for spinal cord compression therapies. In our PB-DLBCL group of patients, the prognosis of patients accepting excisions was not better than the prognosis of patients who did not accept excisions and chemotherapy was the main form of treatment for the PBL patients. Various studies have noted that combined modality therapy (CMT) was better than radio/chemotherapy alone for PBL[@b7][@b11][@b15][@b17]. However, there is still controversy in whether CMT is superior to chemotherapy alone. Cai *et al.*[@b7] reported 116 early PBL cases, with 5-year OS rates of 79% for the CMT group and 69% for the radio/chemotherapy alone groups (P = 0.05) and a multivariable analysis showed that CMT was an independent factor that affects OS. Report by Beal *et al.*[@b15] also revealed that CMT was an independent prognostic risk factor for PBL, with 5-year OS rate of 95% for the CMT group and 78% for the solely radio/chemotherapy groups (P = 0.001). In our study, all of 34 PB-DLBCL patients received chemotherapy and 18 patients (42.1%) received CMT. However, the addition of radiotherapy to chemotherapy did not improve the prognosis of PB-DLBCL in our study. Similar data were also reported in a study by Alencar *et al.*[@b14] and Ramadan *et al.*[@b8] Taken together we believe, regardless of the stage at diagnosis, PBL should still be regarded as a systemic disease like other lymphomas, with systemic chemotherapy being the main treatment. Combined radiotherapy in the present study failed to improve the prognosis of PBL patients, but because of the limited sample size and the results of previous studies, the role of radiotherapy still needs further verification. Whether PBL patients need CMT, the treatment modality should be selected in the clinic individually according to the actual condition of the patient. However, we suggest that surgical resection of the lesion is not appropriate as a preferred treatment for PBL patients.

Rituximab in combination with chemotherapy has been used as standard protocol for CD20 + B-cell non-Hodgkin's lymphoma. The vast majority of the pathological types of PBL are B-cell related, but whether the addition of rituximab can improve the prognosis of PBL patients remains controversial. Ramadan *et al.*[@b8] compared the prognosis between PB-DLBCL patients receiving CHOP/CHOP-like chemotherapy and those receiving an R-CHOP program, and found that rituximab significantly improved PFS. In the report of Alencar *et al.*,[@b14] the trend of prolonged PFS has been apparently improved in PB-DLBCL patients receiving rituximab-CHOP compared to those on a CHOP regime alone, but statistical significance (P = 0.062) was not reached. Also Catlett *et al.*[@b33] and Kim *et al.*[@b39] reported non-significant trend towards improved OS with rituximab combination therapy, which is in agreement with our result. Thus, the role of rituximab in PBL treatments requires further investigation.

Conclusion
==========

By retrospective analysis 61 PBL patients in our single institution, we identified the clinical characteristics and prognosis of PBL in Chinese population. The results showed that the most common pathological type was DLBCL, but the proportion of the T-cell type cases was higher than in the US and Europe. The most common sites invaded were the bones of the spine and the pelvis. High baseline ECOG scores and unachieved CR in initial therapy result in poor prognosis of PB-DLBCL patients. Chemotherapy plays a central role in the treatment of PBL. Though the present result failed to support the use of combined modality for the treatment of PBL, the role of radiotherapy and optimal treatment strategy for PBL warrants further investigation by larger prospective multicenter studies.
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###### General clinical characteristics of 61 patients with PBL.

  Item                         Cases      Proportion (%)
  ------------------------ ------------- ----------------
  Gender                                 
   Male                         38             62.3
   Female                       23             37.7
   Female: Male               1.65: 1    
  Age                                    
   \<60                         46             75.4
   ≥60                          15             24.6
   Median age               45 (13--80)          
  Initial symptom                        
   Pain                         50             82.0
   Nerve compression            20             32.8
   Local mass                    7             11.5
  B symptoms                    19             31.1
  Pathological fracture         13             21.3
  Soft tissue invasion          42             68.9
  Lymph node involvement        27             44.3
  The number of lesions                  
   Single                       28             45.9
   Multiple                     33             54.1
  Stage                                  
   Stage IE                     16             26.2
   Stage IIE                    11             18.1
   Stage IV                     34             55.7
  ECOG score                             
   ≤2                           37             60.7
   \>2                          24             39.3
  LDH                                    
   Normal                       32             52.5
   Elevated                     29             47.5
  IPI score                              
   ≤2                           44             72.1
   \>2                          17             27.9

ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; IPI, International Prognostic Index.

###### Histopathological subtypes of 61 PBL patients.

  Pathological type    Cases   Proportion (%)
  ------------------- ------- ----------------
  DLBCL                 34          55.7
   GCB type             11          18.0
   Non-GCB type         12          19.7
   Undetected           11          18.0
  ALCL                   8          13.1
   ALK(+)                5          8.2
   ALK(−)                3          4.9
  B-LBL                  7          11.5
  MCL                    3          4.9
  MZL                    2          3.3
  T-LBL                  1          1.6
  HL                     4          6.6
  T-cell origin          2          3.3

DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell-like; Non-GCB, non-germinal center B-cell-like; ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; B-LBL, B-lymphoblastic lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; T-LBL, T-lymphoblastic lymphoma; HL, Hodgkin lymphoma.

###### Pathogenic sites of 61 PBL patients.

  Site               Cases (%)     Multiple      Total
  ----------------- ------------ ------------ ------------
  Limbs                                       
   Humerus            3 (11.1)     4 (11.8)     7 (11.5)
   Femur              2 (7.4)      6 (17.6)     8 (13.1)
   Tibia, fibula      3 (11.1)     2 (5.9)      5 (8.2)
  Axial skeleton                              
   Spine              1 (3.7)     25 (73.5)    26 (42.6)
   Pelvis             9 (33.3)    17 (50.0)    26 (42.6)
   Rib cage            0 (0)       5 (14.7)     5 (8.2)
   Shoulder blade     2 (7.4)      2 (5.9)      4 (6.6)
   Clavicle            0 (0)       2 (5.9)      2 (3.3)
   Skull              7 (25.9)     6 (17.6)    13 (21.3)
  Total              27 (100.0)   34 (100.0)   61 (100.0)

###### Treatment modality of 61 PBL patients.

  Treatment                               Cases   Proportion (%)
  -------------------------------------- ------- ----------------
  Chemotherapy                             37          60.7
  Chemotherapy and Radiotherapy            24          39.3
  Surgery                                  18          29.5
   Relieve symptoms or treat fractures     10          16.4
   Resect primary lesions                   8          13.1

###### Effect of histopathological subtypes on the prognosis of patients with PBL.

  Item                   Cases    OS       PFS                                  
  --------------------- ------- ------ ------------ ------- ------ ------------ -------
  Pathological types                                                            
   B cell lymphoma        43     52.1   42.9--61.3   0.771   43.8   35.3--52.3   0.207
   T cell lymphoma        10     44.4   23.3--65.5           45.0   27.6--62.4      
   HL                      4     75.0   53.3--96.7           0.0                    
  Whether to be DLBCL                                                           
   DLBCL                  34     53.0   42.8--63.2   0.805   47.0   37.6--56.4   0.184
   Not DLBCL              23     51.2   37.6--64.8           28.7   17.6--39.8      
  Whether to be ALCL                                                            
   ALCL                    8     75.0   59.7--90.3   0.667   62.5   45.4--80.2   0.633
   Not ALCL               49     49.9   41.2--58.6           37.0   29.3--44.7      
  DLBCL vs. ALCL                                                                
   DLBCL                  34     53.0   42.8--63.2   0.680   47.0   37.6--56.4   0.907
   ALCL                    8     75.0   59.7--90.3           62.5   45.4--80.2      

OS, overall survival; PFS, progression-free survival; CI, confidence interval; HL, Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; ALCL, anaplastic large cell lymphoma.

P-values are shown for the log-rank test between variables.

###### Univariable analysis of 34 PB-DLBCL patients.

  Item                                     Cases    OS       PFS                                    
  --------------------------------------- ------- ------ ------------ --------- ------ ------------ ---------
  Gender                                                                                            
   Male                                     20     57.7   45.1--70.3    0.980    47.9   35.1--60.7    0.805
   Female                                   14     43.3   26.5--60.1             46.4   32.6--60.2       
  Age                                                                                               
   \<60                                     23     60.9   49.7--72.1    0.288    57.6   46.6--68.6    0.040
   ≥60                                      11     25.6   5.2--46.0              18.2   3.0--33.4        
  Pathogenic sites                                                                                  
   Axial skeleton                           19     63.9   51.7--76.1    0.827    58.3   45.8--70.8    0.366
   Limbs                                    15     39.3   23.5--55.1             36.7   23.8--49.6       
  Pathological fracture                                                                             
   Yes                                       9     31.7   13.7--49.7    0.066    33.9   15.7--52.1    0.240
   No                                       25     58.9   46.8--71.0             50.9   40.0--61.8       
  B symptoms                                                                                        
   Yes                                      12     42.9   26.4--29.4    0.084    24.3   10.1--38.5    0.038
   No                                       22     61.1   49.3--72.9             59.3   48.0--70.6       
  ECOG score                                                                                        
   \<2                                      19     71.6   57.2--86.0   \<0.001   68.6   56.6--80.6    0.002
   ≥2                                       15     29.1   16.9--41.3             22.0   10.8--33.2       
  LDH                                                                                               
   Normal                                   16     54.1   38.4--69.8    0.185    60.6   46.6--74.6    0.026
   Elevated                                 18     52.7   40.4--65.0             35.1   23.3--47.0       
  Soft tissue invasion                                                                              
   No                                        7     57.1   32.2--82.0    0.360    57.1   32.2--82.0    0.179
   Yes                                      27     44.9   33.4--56.4             37.1   26.8--47.4       
  Lymph node invasion                                                                               
   No                                       14     68.8   55.5--82.1    0.465    55.0   38.7--71.3    0.121
   Yes                                      20     42.4   28.7--56.1             30.9   19.2--42.6       
  Stage                                                                                             
   Stage I & II                             17     62.9   47.4--78.4    0.021    59.7   46.8--72.6    0.091
   Stage IV                                 17     41.0   27.9--54.1             34.9   21.9--47.9       
  IPI score                                                                                         
   ≤2                                       23     56.4   43.1--69.7    0.034    54.7   43.1--66.3    0.060
   \>2                                      11     40.9   25.3--56.5             31.2   16.4--46.0       
  Molecular subtype                                                                                 
   GCB                                      11     70.1   55.4--84.8    0.193    63.6   49.1--78.1    0.299
   Non-GCB                                  12     20.0   2.9--37.1              20.8   4.1--37.5        
   Undetected                               11                                                           
  Radiotherapy                                                                                      
   Yes                                      18     57.4   44.8--70.0    0.423    43.8   31.9--55.7    0.684
   No                                       16     49.2   32.1--66.3             52.5   37.0--68.0       
  Prophylactic intrathecal chemotherapy                                                             
   Yes                                      10     75.0   59.2--90.8    0.560    63.0   45.3--80.7    0.472
   No                                       24     44.9   32.9--56.9             41.6   30.9--52.3       
  Surgical resection                                                                                
   Yes                                       4     50.0   14.6--85.4    0.457    50.0   14.6--85.4    0.323
   No                                       30     54.1   44.1--64.1             45.0   35.2--54.8       
  Whether CR in initial therapy                                                                     
   Yes                                      20     74.4   63.1--85.7   \<0.001   71.1   59.9--82.3   \<0.001
   No                                       14     17.1   3.2--31.0              9.2    0.5--17.9        
  Rituximab                                                                                         
   Used                                     21     48.4   34.6--62.2    0.494    44.9   32.3--57.5    0.432
   Unused                                   13     60.6   46.8--74.4             44.0    29.7--5         

OS, overall survival; PFS, progression-free survival; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; IPI, International Prognostic Index; GCB, germinal center B-cell-like; Non-GCB, non-germinal center B-cell-like; CR, complete remission.

P-values are shown for the log-rank test between variables.

###### Multivariable analysis on the effect to survival of PB-DLBCL patients.

  Risk factors                                       OS          PFS                                      
  ------------------------------------------------ ------- --------------- ------- ------- -------------- -------
  ECOG score (ECOG ≥2 *vs.* ECOG \<2)               4.840   1.261--18.578   0.022                           NS
  Response to initial treatment (CR *vs.* no CR)    0.245   0.071--0.850    0.027   0.112   0.038--0.332   0.001

RR, Relative risk; CI, confidence interval; NS, No statistical significance; ECOG, Eastern Cooperative Oncology Group; CR, complete remission.
